| Identification | Back Directory | [Name]
(+)-Piresil-4-O-beta-D-glucopyraside | [CAS]
69251-96-3 | [Synonyms]
(+)-pinor
Pinoresinol 4-glucoside
Pinoresinol 4-O-glucoside
(+)-pinoresinol-β-D-glucoside
(+)-Piresil-4-O-β-D-glucopyraside
Pinoresinol 4-O-β-D-glucopyranoside
(+)-Piresil-4-O-beta-D-glucopyraside
(+)-Pinoresinol-4-O-β-D-glucopyraside
Pinoresinol 4-O-beta-D-glucopyranoside
(+)-pinoresinol-4-O-β-D-glucopyranoside
(+)-pinoresinol-4-O-beta-D-glucopyranoside
3,5-dibromo-benzoic acid,3,5-dibromobenzoic acid
(+)-pinoresinol-β-D-glucoside(+)-pinoresinol-4-O-beta-D-glucopyranoside
4-[(1S,3aR,4S,6aR)-4-(4-Hydroxy-3-methoxyphenyl)tetrahydro-1H,3H-furo[3,4-c]furan-1-yl]-2-methoxyphenylβ-D-glucopyranoside
4-[(1S,3aR,4S,6aR)-4-(4-Hydroxy-3-methoxyphenyl)tetrahydro-1H,3H- furo[3,4-c]furan-1-yl]-2-methoxyphenyl β-D-glucopyranoside
β-D-Glucopyranoside, 2-methoxy-4-[(1S,3aR,4S,6aR)-tetrahydro-4-(4-hydroxy-3-methoxyphenyl)-1H,3H-furo[3,4-c]furan-1-yl]phenyl | [Molecular Formula]
C26H32O11 | [MDL Number]
MFCD17214935 | [MOL File]
69251-96-3.mol | [Molecular Weight]
520.53 |
| Chemical Properties | Back Directory | [Melting point ]
102-104 °C(Solv: methanol (67-56-1)) | [Boiling point ]
752.5±60.0 °C(Predicted) | [density ]
1.418±0.06 g/cm3(Predicted) | [storage temp. ]
2-8°C | [form ]
Solid | [pka]
9.84±0.35(Predicted) | [color ]
White to light yellow |
| Hazard Information | Back Directory | [Chemical Properties]
Soluble in methanol, ethanol, DMSO and other organic solvents, derived from Forsythia. | [Uses]
(+)-Piresil-4-O-beta-D-glucopyraside is used for content determination/identification/pharmacological experiments, etc. | [Definition]
ChEBI: (+)-Pinoresinol 4-O-glucoside is a lignan and a glycoside. | [Biological Activity]
Pinoresinol 4-O-β-D-glucopyranoside ((+)-Pinoresinol 4-O-β-D-glucopyranoside) is the main active furofuranoside lignan in Forsythia. It has antioxidant, hypotensive and cyclic adenosine monophosphate (cAMP) phosphodiesterase inhibitory effects. | [in vivo]
Pinoresinol 4-O-β-D-glucopyranoside (50 mg/kg; p.o.; 20 days for hepatoprotective activity test, 10 days for antihyperglycaemic activity test) exhibits hepatoprotective activity by lowering AST and ALT levels in CCl4 (HY-Y0298)-induced hepatotoxicity mice, and shows antihyperglycaemic activity by causing a prominent decline in serum glucose level and a promising elevation in insulin level in Streptozotocin (HY-13753)-treated mice[4].
Pinoresinol 4-O-β-D-glucopyranoside (25-50 mg/kg; p.o.; twice with the second dose 1 h before pilocarpine injection) ameliorates the seizures in a dose-dependent manner in lithium/Pilocarpine (HY-B0726A)-induced epileptic seizures rats, manifested by retarding seizure onset, reducing the number of rats developing seizures, and enhancing the survival of animals after seizure exposure[7].
| Animal Model: | Male Swiss albino mice (weight: 27-30 g), CCl4-induced hepatotoxicity model and Streptozotocin-induced hyperglycaemia model[4] | | Dosage: | 50 mg/kg b.w. | | Administration: | Oral gavage (p.o.), 20 days in the hepatotoxicity experiment; 10 days in the hyperglycaemia experiment | | Result: | Led to a 33.94% decline in AST, a 3.01% decline in ALT, and a 49.96% decline in LPO levels (in the CCl4-induced hepatotoxicity model).
Significantly enhanced CAT, SOD, and TAS levels by 130%, 90.45%, and 61.39% respectively compared to the CCl4-treated group (in the CCl4-induced hepatotoxicity model).
Caused a 37.83% reduction in serum glucose level and a 25.37% increase in insulin level (in the Streptozotocin-induced hyperglycaemia model).
Reduced lipid peroxide levels by 51.77% and increased serum levels of CAT, SOD, and TAS by 93.02%, 70.79%, and 101.90%, respectively (in the Streptozotocin-induced hyperglycaemia model).
|
|
|
|